Exponential Medicine is a unique and intensive four-day experience that gathers world-class faculty, innovators and organizations from across the biomedical and technology spectrum to explore and leverage the convergence of fast moving technologies in the reinvention and future of health and medicine.
Google’s new quantum computing chip, Willow, has set a groundbreaking standard by achieving unparalleled speed and precision, outperforming supercomputers in specific tasks by millions of times. This revolutionary chip enhances quantum error correction, making scalable quantum systems a reality and unlocking new possibilities for artificial intelligence, scientific research, and real-world problem-solving. Willow’s success marks a major milestone in the integration of quantum computing and AI, driving innovation across industries.
Don’t let AI leave you behind — get updates at https://airevolution.cc.
🔍 Key Topics:
Google’s Willow chip and its revolutionary quantum computing advancements.
How quantum error correction enables scalable and stable systems with unmatched performance.
The integration of quantum computing and AI to tackle problems beyond classical limits.
🎥 What You’ll Learn:
Why Willow represents a major breakthrough in quantum computing and AI innovation.
How it reduces errors and enhances performance for real-world applications in medicine, energy, and more.
The potential of quantum AI to transform industries and solve previously unsolvable challenges.
📊 Why It Matters:
This video explores Google’s revolutionary quantum chip, Willow, and its impact on the future of computation and AI, highlighting its scalability, precision, and groundbreaking applications in science and industry.
DISCLAIMER:
The preprint, not yet peer-reviewed, is the latest from a global consortium that hunts down potential new genes. Ever since the Human Genome Project completed its first draft at the turn of the century, scientists have tried to decipher the genetic book of life. Buried within the four genetic letters—A, T, C, and G—and the proteins they encode is a wealth of information that could help tackle our most frustrating medical foes, such as cancer.
The Human Genome Project’s initial findings came as a surprise. Scientists found less than 30,000 genes that build our bodies and keep them running—roughly a third of that previously predicted. Now, roughly 20 years later, as the technologies that sequence our DNA or map proteins have become increasingly sophisticated, scientists are asking: “What have we missed?”
The new study filled the gap by digging into relatively unexplored portions of the genome. Called “non-coding,” these parts haven’t yet been linked to any proteins. Combining several existing datasets, the team zeroed in on thousands of potential new genes that make roughly 3,000 miniproteins.
Researchers suggest an application to FDA may be made within the next 12 months, requesting approval to carry out a human clinical trial with the gene therapy.
Tiny implantable sensors are helping University of Oregon researchers optimize the process of recovery from severe bone injuries.
Scientists at the UO’s Phil and Penny Knight Campus for Accelerating Scientific Impact have developed miniature implantable sensors that transmit real-time data about what’s happening at an injury site. In a new study, they use the technology to show that a resistance-training rehabilitation program can significantly improve femur injuries in rats in just eight weeks.
The sensors provide a window into the mechanical properties of the bone, giving scientists detailed ongoing data about the process of healing. If someday applied in humans, these sensors could allow doctors to better tailor a rehabilitation program to an individual patient, monitoring their progress and adjusting the exercises along the way.
Summary
In this Machine Learning project, we develop a hypo Thyroid Disease detection using the Decision Tree and KNN Classifier. We hope you have learned something new from this project.
Immunotherapy has changed the way physicians treat patients and has improved standard of care for many different tumors. Unfortunately, solid tumors are still treated with limited efficacy. In many cases, solid tumors are not recognized by the immune system and progress throughout the body. Tumor growth unnoticed by the immune system is due to immune suppressive mechanisms that the cancer controls. These mechanisms dysregulate immune cells from functioning properly. Various tumors escape immune cell detection and by the time it is clinically detected, the cancer has moved to an advanced stage.
Although there are many solid tumors that rapidly progress, one in particular includes glioblastoma. Glioblastoma is an aggressive brain tumor that extends into the spinal cord and results in poor prognosis. It arises from glial cells which support nerves and aids in brain damage repair. Unfortunately, scientists are still unsure on how glioblastoma occurs. Symptoms can vary based on location of tumor in the brain, but common features include headaches, nausea, seizures, vision changes, difficulty speaking, and change in personality. Currently, there is no cure for glioblastoma and the treatments are limited based on the aggressive stage at diagnosis. Scientists are working to improve quality of life and prolong survival through different immunotherapies, which redirect immune cells toward the tumor.
There are various ways to study therapy in a laboratory including the use of animal models and cells in a dish. However, a more recent form of model has emerged in the last few decades that can help scientists better mimic a human tumor. This new technology are cells cultured in a dish that are produced to form a 3D tumor. These cell cultures are referred to as ‘organoids’ and they are designed to grow and act like a tumor within the body. A group at the University of Pennsylvania (UPenn) is using this model to test tumor response to novel immunotherapies.
Vaccines have advanced the field of health and medicine throughout the last century. They are commonly given before a disease can occur to expose individuals to invading pathogens. Vaccines given as a preventative treatment helps the immune system build an immune response against disease that the person may encounter in the future. When an individual gets a shot at the doctor’s office they are injecting an attenuated version of the disease. The body will then recognize this pathogen as foreign and build an immune response against it. This is why many times a person feels sick after a few days from a vaccination – the body is activating the immune system to eliminate the disease.
Many types of vaccines exist and are developed to optimize delivery of attenuated pathogen. Arguably, the most well-known type of vaccine uses messenger ribonucleic acid (mRNA). These vaccines work by delivering mRNA of a virus, which allows human cells to produce viral protein. The immune system responds strongly to the viral proteins and targets them with different immune cells, while also generating antibodies against it. Once the body has built this response, the immune system can more easily target the same virus in the future. This recognition of specific infections is referred to as immunological memory. Currently, the only mRNA vaccines Food and Drug Administration (FDA) approved are for COVID-19. However, the efficient use of mRNA vaccines for COVID-19 have scientists wondering if this format can be used in other disease settings, including cancer.
A recent article in Nature Communications, by Dr. Damya Laoui and others introduce a novel therapeutic approach in which mRNA is integrated into nanoparticles to overcome tumor progression. Laoui is a group leader at Vlaams Instituut voor Biotechnologie (VIB) in Brussels, Belgium. Her work focuses on immune cell activation through specific immune cells known as macrophages and dendritic cells. Laoui also works on developing novel personalized immunotherapies for patients with hard-to-treat cancers.
Researchers think certain common viruses may trigger some autoimmune conditions—alone or in concert with other factors. A recent Office of Autoimmune Disease Research (OADR)-Office of Research on Women’s Health Science Talks series focused on understanding the triggers of autoimmunity and advancing research.
Almost 80 percent of people living with an autoimmune disease are women. It’s estimated there are 80–120 autoimmune diseases. These chronic and often debilitating diseases have no known cures. Some combination of genetics, immune regulation and the environment work together to form an “endotype” for each autoimmune disease patient, explained Dr. Judith James of the Oklahoma Medical Research Foundation.
Her presentation focused on lupus, or systemic lupus erythematosus (SLE), which disproportionately affects women. Nine women are diagnosed with SLE for every male. In SLE, the immune system attacks healthy tissue, causing inflammation and occasionally permanent damage.
If you looked at two snapshots of the same maple tree taken in July and December, you’d see a dramatic change from summer’s full green crown to winter’s bare branches. What those two photos don’t show you, however, is how the change occurred—gradually or all at once? In truth, deciduous trees tend to hold out for an environmental signal—a change in light or temperature—and then shed all their leaves within just a week or two.
When it comes to aging, we may be more like these trees than we realized.
According to new work from Rockefeller’s Laboratory of Single-Cell Genomics and Population Dynamics, mammals follow a similar aging trajectory at the cellular level. As described in a new paper in Science, lab head Junyue Cao and his colleagues used single-cell sequencing to simultaneously scan more than 21 million cells from every major mouse organ across five stages of life. This enormous collection is now the world’s largest cellular atlas within a single study.
